At least 5 dead and 19 injured in chemical plant explosion in China, CCTV reports
BEIJING — A huge explosion rocked a chemical plant in China's eastern Shandong province around noon Tuesday, killing at least five people and injuring 19, according to state broadcaster CCTV. An additional six people remain missing.
The blast was powerful enough to knock out the windows at a storage warehouse more than two miles (three kilometers) away from the factory, according to a video shared by a local resident, who declined to give his name out of concern for retaliation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the California-based company said on Wednesday. Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said. Under the deal, Novo will receive exclusive global rights to develop and commercialize so-called non-incretin oral therapies, which belong to a different class of medicines than its popular weight-loss and diabetes drugs Wegovy and Ozempic. WHY IT'S IMPORTANT Novo has been trying to strengthen its foothold in the potential $150 billion weight-loss drug market through the development of next-generation treatments as well as acquisitions and partnerships. In March, the company signed two licensing deals and gained access to experimental obesity drugs from Lexicon Pharmaceuticals and China-based United Laboratories International. CONTEXT Novo in May ousted CEO Lars Fruergaard Jorgensen over concerns the Danish company - a world leader in the lucrative weight-loss drug market - was losing its first-mover advantage. The company's shares have plunged since hitting a record high in June last year as competition, particularly from U.S. rival Eli Lilly, eats into its market share, while Novo's pipeline of new drugs has failed to impress investors. BY THE NUMBERS As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from their collaboration.
Yahoo
4 hours ago
- Yahoo
Three killed in methanol reservoir fire in Iran's south
DUBAI (Reuters) -At least three people have died and ten people were injured when a methanol reservoir caught fire in a port in Iran's southern province of Bushehr, state media IRNA reported on Wednesday. State TV said a vessel carrying methanol, which was docked at the port of Bandar Dayyer and belongs to the Kaveh Petrochemicals Company, had caught fire for reasons which were not yet known. "Considering the extent of the fire, it is likely that the number of dead and injured will rise," the head of the province's emergency services said. In April, a large explosion took place at the Shahid Rajaee port in southern Iran killing 57 people, with some officials blaming poor storage of chemicals in containers. An official investigation into the incident has yet to be completed.
Medscape
4 hours ago
- Medscape
Can a TKI Boost Anti-PD-L1 Activity in NSCLC?
Can adding a TKI that targets programmed death ligand 1 (PD-L1) to a monoclonal antibody that also targets PD-L1 improve outcomes over the monoclonal antibody alone in locally advanced, unresectable non-small cell lung cancer (NSCLC)? Researchers in China have come in with a qualified yes. The authors of the new study found that a combination of anlotinib, an oral small-molecule TKI, and benmelstobart (TQB2450), a humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody that targets PD-L1, improved progression-free survival (PFS) compared with benmelstobart alone after concurrent/sequential chemoradiotherapy (60 Gray ± 10%). A downside of taking the TKI was a significant increase in side effects, Ming Chen, MD, PhD, lead investigator of the R-ALPS trial, reported at American Society of Clinical Oncology (ASCO) 2025. Study Results 'Our key finding demonstrated significant improvement in median PFS with the combination of benmelstobart plus anlotinib, with a median PFS of 15.1 months compared to 9.7 months with benmelstobart alone and 4.2 months with placebo,' said Chen, while presenting the abstract at the meeting. PFS was the primary endpoint of the study. Ming Chen, MD, PhD 'This translated into a reduced risk of disease progression with a hazard ratio of 0.49 for the combination arm and 0.53 for benmelstobart alone,' vs placebo, said Chen, who is director of Radiation Oncology at the Sun Yat-sen University Cancer Center in Guangzhou, China. The P values for both were less than .0001. Chen reported results of an interim analysis of the phase 3 R-ALPS study, which randomized 553 patients to one of three treatment groups after all received concurrent/sequential chemoradiotherapy: Benmelstobart alone, benmelstobart plus anlotinib, or placebo. Twelve-month PFS rates were 54.9% in the combination group, 45.7% in the benmelstobart alone group, and 26.4% in the placebo group. The data analysis of overall survival rates has not been completed, Chen said. Among secondary endpoints, overall response rates were 25.6% ( P = .01), 23.3 ( P = .0318), and 12.9% for the combination, benmelstobart alone, and placebo groups, respectively. The disease control rates were 84.5% ( P = .0067) and 86.1% ( P = .0023) for the combination and benmelstobart alone groups, respectively, and was 70.5% for the placebo group. Safety Profile 'Manageable' or 'Significant'? The combination group had consistently higher rates of adverse events than the other two groups. Chen said the safety profile of adding anlotinib to benmelstobart was 'manageable,' while Shankar Siva, PhD, MBBS, a discussant at the oral abstracts session, characterized the toxicity profile of the study as 'significant.' Shankar Siva, PhD, MBBS Overall, the rates of grade 3-5 treatment-related adverse events (TRAEs) were 50% in the combination group, 32% in the benmelstobart alone group, and 21% in the placebo group. The rates of serious TRAEs were 38.3%, 33% and 26.5%, respectively. Hematologic toxicities were not significantly different across the three groups, Chen said, but the following four biochemical measures were significantly elevated in the combination group: Antistreptokinase, creatine phosphokinase, thyroid-stimulating hormone, and amylase. Among the grade 3-5 non-hematologic TRAEs, rates of infectious pneumonia, hypertension, and hemoptysis were significantly higher in the combination group: 8.1%, 8.6%, and 2.4%, respectively, vs 4.7%, 0.9%, and 0.5% in the benmelstobart alone group and 5.3%, 1.8%, and 0.8% in the placebo group. Chen added that the rates of radiation pneumonitis and immune pneumonitis 'were very mild in all three arms,' with rates below 3%. Elaborating on his different take on the combination treatment's safety profile from Chen's, Siva said the incidence of high-grade adverse events in this study was notable. 'More targeted or bispecific TKIs' might be worth exploring in a combination treatment after chemoradiotherapy for NSCLC to improve the safety profile, he said, during the session. Knowing biomarkers of benefit and potential toxicity would also be important for using multitarget TKIs in combination therapies after chemoradiotherapy for NSCLS, noted Siva, who is a radiation oncologist at Peter MacCallum Cancer Centre in Melbourne, Australia. One of the limitations of the study was that all patients were Chinese, Chen said. Anlotinib was approved for advanced NSCLC in China in 2019. Chia Tai TianQing Pharmaceutical Group funded the study. Chen reported having no relevant financial relationships. Siva reported having financial relationships with AstraZeneca, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, and Varian Medical Systems.
